Načítá se...
P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
The P16 (CDKN2A(ink4a)) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA methylation in cancers. It is well known that cancer cells with P16 deletion are more sensitive...
Uloženo v:
| Vydáno v: | PLoS One |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Public Library of Science
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6814222/ https://ncbi.nlm.nih.gov/pubmed/31652270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0223084 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|